Moderate Psoriasis-Pipeline Review, H1 2015

Moderate Psoriasis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6598IDB
  • |
  • Pages: 137
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Moderate Psoriasis-Pipeline Review, H1 2015


Global Markets Direct's, 'Moderate Psoriasis-Pipeline Review, H1 2015', provides an overview of the Moderate Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Moderate Psoriasis Overview 9

Therapeutics Development 10

Pipeline Products for Moderate Psoriasis-Overview 10

Pipeline Products for Moderate Psoriasis-Comparative Analysis 11

Moderate Psoriasis-Therapeutics under Development by Companies 12

Moderate Psoriasis-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Moderate Psoriasis-Products under Development by Companies 17

Moderate Psoriasis-Companies Involved in Therapeutics Development 20

AbGenomics International, Inc. 20

Almirall, S.A. 21

Amgen Inc. 22

ApoPharma Inc. 23

Avexxin AS 24

Boehringer Ingelheim GmbH 25

Convoy Therapeutics, Inc. 26

Covagen AG 27

Delenex Therapeutics AG 28

Eli Lilly and Company 29

GlycoMar Limited 30

Idera Pharmaceuticals, Inc. 31

Johnson & Johnson 32

Merck KGaA 33

OPKO Health, Inc. 34

Pfizer Inc. 35

Sandoz International GmbH 36

Soligenix, Inc. 37

Sun Pharmaceutical Industries Inc. 38

Syntrix Biosystems, Inc. 39

UCB S.A. 40

Valeant Pharmaceuticals International, Inc. 41

XenoPort, Inc. 42

Moderate Psoriasis-Therapeutics Assessment 43

Assessment by Monotherapy Products 43

Assessment by Target 44

Assessment by Mechanism of Action 46

Assessment by Route of Administration 48

Assessment by Molecule Type 50

Drug Profiles 52

AbGn-168H-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

adalimumab biosimilar-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

adalimumab biosimilar-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

AKP-11-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

aminopterin sodium-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

AVX-001-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

baricitinib-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

BI-655066-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

brodalumab-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

certolizumab pegol-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

COVA-322-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

cyclosporine-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

dimethyl fumarate-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

DLX-105-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

DLX-3003-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

etanercept biosimilar-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

GLY-2028-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

guselkumab-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

IDP-118-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

IMO-8400-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

ixekizumab-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

lunacalcipol-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

MSB-0010841-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

orilotimod potassium-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

PF-04965842-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

SGX-301-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

tazarotene-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

tildrakizumab-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

UCB-5857-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

ustekinumab-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

XP-23829-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Moderate Psoriasis-Recent Pipeline Updates 101

Moderate Psoriasis-Dormant Projects 131

Moderate Psoriasis-Discontinued Products 133

Moderate Psoriasis-Product Development Milestones 134

Featured News & Press Releases 134

Sep 11, 2014: Delenex Announces New Clinical Data 134

Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 134

Appendix 136

Methodology 136

Coverage 136

Secondary Research 136

Primary Research 136

Expert Panel Validation 136

Contact Us 136

Disclaimer 137

List of Tables

Number of Products under Development for Moderate Psoriasis, H1 2015 10

Number of Products under Development for Moderate Psoriasis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Development by Companies, H1 2015 (Contd..2) 19

Moderate Psoriasis-Pipeline by AbGenomics International, Inc., H1 2015 20

Moderate Psoriasis-Pipeline by Almirall, S.A., H1 2015 21

Moderate Psoriasis-Pipeline by Amgen Inc., H1 2015 22

Moderate Psoriasis-Pipeline by ApoPharma Inc., H1 2015 23

Moderate Psoriasis-Pipeline by Avexxin AS, H1 2015 24

Moderate Psoriasis-Pipeline by Boehringer Ingelheim GmbH, H1 2015 25

Moderate Psoriasis-Pipeline by Convoy Therapeutics, Inc., H1 2015 26

Moderate Psoriasis-Pipeline by Covagen AG, H1 2015 27

Moderate Psoriasis-Pipeline by Delenex Therapeutics AG, H1 2015 28

Moderate Psoriasis-Pipeline by Eli Lilly and Company, H1 2015 29

Moderate Psoriasis-Pipeline by GlycoMar Limited, H1 2015 30

Moderate Psoriasis-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 31

Moderate Psoriasis-Pipeline by Johnson & Johnson, H1 2015 32

Moderate Psoriasis-Pipeline by Merck KGaA, H1 2015 33

Moderate Psoriasis-Pipeline by OPKO Health, Inc., H1 2015 34

Moderate Psoriasis-Pipeline by Pfizer Inc., H1 2015 35

Moderate Psoriasis-Pipeline by Sandoz International GmbH, H1 2015 36

Moderate Psoriasis-Pipeline by Soligenix, Inc., H1 2015 37

Moderate Psoriasis-Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 38

Moderate Psoriasis-Pipeline by Syntrix Biosystems, Inc., H1 2015 39

Moderate Psoriasis-Pipeline by UCB S.A., H1 2015 40

Moderate Psoriasis-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 41

Moderate Psoriasis-Pipeline by XenoPort, Inc., H1 2015 42

Assessment by Monotherapy Products, H1 2015 43

Number of Products by Stage and Target, H1 2015 45

Number of Products by Stage and Mechanism of Action, H1 2015 47

Number of Products by Stage and Route of Administration, H1 2015 49

Number of Products by Stage and Molecule Type, H1 2015 51

Moderate Psoriasis Therapeutics-Recent Pipeline Updates, H1 2015 101

Moderate Psoriasis-Dormant Projects, H1 2015 131

Moderate Psoriasis-Dormant Projects (Contd..1), H1 2015 132

Moderate Psoriasis-Discontinued Products, H1 2015 133

List of Figures

Number of Products under Development for Moderate Psoriasis, H1 2015 10

Number of Products under Development for Moderate Psoriasis-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 43

Number of Products by Top 10 Targets, H1 2015 44

Number of Products by Stage and Top 10 Targets, H1 2015 44

Number of Products by Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Top 10 Routes of Administration, H1 2015 48

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 49

Number of Products by Top 10 Molecule Types, H1 2015 50

Number of Products by Stage and Top 10 Molecule Types, H1 2015 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbGenomics International, Inc.

Almirall, S.A.

Amgen Inc.

ApoPharma Inc.

Avexxin AS

Boehringer Ingelheim GmbH

Convoy Therapeutics, Inc.

Covagen AG

Delenex Therapeutics AG

Eli Lilly and Company

GlycoMar Limited

Idera Pharmaceuticals, Inc.

Johnson & Johnson

Merck KGaA

OPKO Health, Inc.

Pfizer Inc.

Sandoz International GmbH

Soligenix, Inc.

Sun Pharmaceutical Industries Inc.

Syntrix Biosystems, Inc.


Valeant Pharmaceuticals International, Inc.

XenoPort, Inc.

Moderate Psoriasis Therapeutic Products under Development, Key Players in Moderate Psoriasis Therapeutics, Moderate Psoriasis Pipeline Overview, Moderate Psoriasis Pipeline, Moderate Psoriasis Pipeline Assessment

select a license
Single User License
USD 2000 INR 144820
Site License
USD 4000 INR 289640
Corporate User License
USD 6000 INR 434460



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]